Illuminating p53 function in cancer with genetically engineered mouse models

Seminars in Cell and Developmental Biology

Volumn 27, Issue , 2014, Pages 74-85

  Garcia, Patty B ^a   Attardi, Laura D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mouse models; P53; Tumor suppression

Indexed keywords

PROTEIN P53;

CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE TARGETING; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; ANIMAL; CELL CYCLE CHECKPOINT; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETIC ENGINEERING; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; MISSENSE MUTATION; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

MUS;

ANIMALS; CELL CYCLE CHECKPOINTS; GENETIC ENGINEERING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE, KNOCKOUT; MUTATION, MISSENSE; NEOPLASMS, EXPERIMENTAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901258694     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2013.12.014     Document Type: Review

References (118)

1. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137(May):413.
2. Brady C.A., Attardi L.D. p53 at a glance. Journal of Cell Science 2010, 123(August):2527.
3. Malkin D. Li-Fraumeni syndrome. Genes and Cancer 2011, 2(April):475.
4. Purdie C.A., Harrison D.J., Peter A., Dobbie L., White S., Howie S.E., et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994, 9(February):603.
5. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., et al. Tumor spectrum analysis in p53-mutant mice. Current Biology: CB 1994, 4(January):1.
6. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356(March):215.
7. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nature Reviews Cancer 2004, 4(October):793.
8. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91(October):325.
9. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378(November):203.
10. Wade M., Wang Y.V., Wahl G.M. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends in Cell Biology 2010, 20(May):299.
11. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(July):15.
12. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445(February):656.
13. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nature Reviews Molecular Cell Biology 2008, 9(May):402.
14. Meek D.W., Anderson C.W. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harbor Perspectives in Biology 2009, 1(December):a000950.
15. Murray-Zmijewski F., Slee E.A., Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nature Reviews Molecular Cell Biology 2008, 9(September):702.
16. Attardi L.D., Donehower L.A. Probing p53 biological functions through the use of genetically engineered mouse models. Mutation Research 2005, 576(August):4.
17. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO Journal 1998, 17(August):4657.
18. Kuperwasser C., Hurlbut G.D., Kittrell F.S., Dickinson E.S., Laucirica R., Medina D., et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. American Journal of Pathology 2000, 157(December):2151.
19. Lin S.C., Lee K.F., Nikitin A.Y., Hilsenbeck S.G., Cardiff R.D., Li A., et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and negative mouse mammary tumors with high frequency of metastasis. Cancer Research 2004, 64(May):3525.
20. Shai A., Pitot H.C., Lambert P.F. p53 loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Research 2008, 68(April):2622.
21. Gostissa M., Bianco J.M., Malkin D.J., Kutok J.L., Rodig S.J., Morse III H.C., et al. Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(February):2934.
22. Attardi L.D., Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cellular and Molecular Life Sciences: CMLS 1999, 55(January):48.
23. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer 2009, 9(October):701.
24. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation 2007, 28(June):622.
25. Muller P.A., Vousden K.H. p53 mutations in cancer. Nature Cell Biology 2013, 15(January):2.
26. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265(July):346.
27. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Molecular and Cellular Biology 1989, 9(September):3982.
28. Lee J.M., Abrahamson J.L., Kandel R., Donehower L.A., Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 1994, 9(December):3731.
29. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics 1995, 9(March):305.
30. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., et al. Gain of function mutations in p53. Nature Genetics 1993, 4(May):42.
31. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119(December):861.
32. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119(December):847.
33. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001, 20(January):320.
34. Liu D.P., Song H., Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010, 29(February):949.
35. Song H., Hollstein M., Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nature Cell Biology 2007, 9(May):573.
36. Mello S.S., Attardi L.D. Not all p53 gain-of-function mutants are created equal. Cell Death and Differentiation 2013, 20(July):855.
37. Hanel W., Marchenko N., Xu S., Yu S.X., Weng W., Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death and Differentiation 2013, 20(July):898.
38. Lu X., Liu D.P., Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 2013, 32(June):2900.
39. Johnson T.M., Hammond E.M., Giaccia A., Attardi L.D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genetics 2005, 37(February):145.
40. Lin J., Chen J., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes and Development 1994, 8(May):1235.
41. Brady C.A., Jiang D., Mello S.S., Johnson T.M., Jarvis L.A., Kozak M.M., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145(May):571.
42. Lozano G., Zambetti G.P. What have animal models taught us about the p53 pathway?. Journal of Pathology 2005, 205(January):206.
43. Jiang D., Brady C.A., Johnson T.M., Lee E.Y., Park E.J., Scott M.P. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(October):17123.
44. Candau R., Scolnick D.M., Darpino P., Ying C.Y., Halazonetis T.D., Berger S.L. Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 1997, 15(August):807.
45. Venot C., Maratrat M., Sierra V., Conseiller E., Debussche L. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 1999, 18(April):2405.
46. Zhu J., Zhou W., Jiang J., Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. Journal of Biological Chemistry 1998, 273(May):13030.
47. Gaidarenko O., Xu Y. Transcription activity is required for p53-dependent tumor suppression. Oncogene 2009, 28(December):4397.
48. Hinkal G., Parikh N., Donehower L.A. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS ONE 2009, 4:e6654.
49. Efeyan A., Garcia-Cao I., Herranz D., Velasco-Miguel S., Serrano M. Tumour biology: policing of oncogene activity by p53. Nature 2006, 443(September):159.
50. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443(September):214.
51. Johnson T.M., Meade K., Pathak N., Marques M.R., Attardi L.D. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(January):1215.
52. Liu G., Parant J.M., Lang G., Chau P., Chavez-Reyes A., El-Naggar A.K. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genetics 2004, 36(January):63.
53. Ludwig R.L., Bates S., Vousden K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Molecular and Cellular Biology 1996, 16(September):4952.
54. Barboza J.A., Liu G., Ju Z., El-Naggar A.K., Lozano G. p21 Delays tumor onset by preservation of chromosomal stability. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(December):19842.
55. Schlereth K., Heyl C., Krampitz A.M., Mernberger M., Finkernagel F., Scharfe M., et al. Characterization of the p53 cistrome - DNA binding cooperativity dissects p53's tumor suppressor functions. PLoS Genetics 2013, 9(August):e1003726.
56. Timofeev O., Schlereth K., Wanzel M., Braun A., Nieswandt B., Pagenstecher A., et al. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Reports 2013, 3(May):1512.
57. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107(October):137.
58. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137(May):609.
59. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Molecular Cell 2006, 24(December):841.
60. Tang Y., Luo J., Zhang W., Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Molecular Cell 2006, 24(December):827.
61. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133(May):612.
62. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149(June):1269.
63. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(December):15335.
64. Toledo T., Lee C.J., Krummel K.A., Rodewald L.W., Liu C.W., Wahl G.M. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Molecular and Cellular Biology 2007, 27(February):1425.
65. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO Journal 1998, 17(August):4668.
66. Baptiste N., Friedlander P., Chen X., Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 2002, 21(January):9.
67. Sakamuro D., Sabbatini P., White E., Prendergast G.C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997, 15(August):887.
68. Berger M., Vogt Sionov R., Levine A.J., Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. Journal of Biological Chemistry 2001, 276(February):3785.
69. Wulf G.M., Liou Y.C., Ryo A., Lee S.W., Lu K.P. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. Journal of Biological Chemistry 2002, 277(December):47976.
70. Zacchi P., Gostissa M., Uchida T., Salvagno C., Avolio F., Volinia S., et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 2002, 419(October):853.
71. Zheng H., You H., Zhou X.Z., Murray S.A., Uchida T., Wulf G., et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002, 419(October):849.
72. Toledo F., Krummel K.A., Lee C.J., Liu C.W., Rodewald L.W., Tang M., et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006, 9(April):273.
73. Slatter T.L., Ganesan P., Holzhauer C., Mehta R., Rubio C., Williams G., et al. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death and Differentiation 2010, 17(March):540.
74. Campbell H.G., Mehta R., Neumann A.A., Rubio C., Baird M., Slatter T.L., et al. Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). Oncogene 2013, 32(February):827.
75. Salvioli S., Bonafé M., Barbi C., Storci G., Trapassi C., Tocco F., et al. p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 2005, 4(September):1264.
76. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics 2003, 33(March):357.
77. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23(April):3328.
78. Frank A.K., Leu J.I., Zhou Y., Devarajan K., Nedelko T., Klein-Szanto A., et al. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Molecular and Cellular Biology 2011, 31(March):1201.
79. Zhu F., Dollé M.E., Berton T.R., Kuiper R.V., Capps C., Espejo A., et al. Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Research 2010, 70(July):5851.
80. Chao C., Hergenhahn M., Kaeser M.D., Wu Z., Saito S., Iggo R., et al. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. Journal of Biological Chemistry 2003, 278(October):41028.
81. Sluss H.K., Armata H., Gallant J., Jones S.N. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Molecular and Cellular Biology 2004, 24(February):976.
82. Armata H.L., Garlick D.S., Sluss H.K. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Research 2007, 67(December):11696.
83. MacPherson D., Kim J., Kim T., Rhee B.K., Van Oostrom C.T., DiTullio R.A., et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO Journal 2004, 23(September):3689.
84. Wu Z., Earle J., Saito S., Anderson C.W., Appella E., Xu Y. Mutation of mouse p53 Ser23 and the response to DNA damage. Molecular and Cellular Biology 2002, 22(April):2441.
85. Chao C., Herr D., Chun J., Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO Journal 2006, 25(June):2615.
86. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102(September):849.
87. Saito S., Yamaguchi H., Higashimoto Y., Chao C., Xu Y., Fornace A.J., et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. Journal of Biological Chemistry 2003, 278(September):37536.
88. Feng L., Hollstein M., Xu Y. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 2006, 5(December):2812.
89. Bruins W., Zwart E., Attardi L.D., Iwakuma T., Hoogervorst E.M., Beems R.B., et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Molecular and Cellular Biology 2004, 24(October):8884.
90. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., Pluquet O., Hatzoglou M., et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes and Development 2004, 18(February):261.
91. Blaydes J.P., Luciani M.G., Pospisilova S., Ball H.M., Vojtesek B., Hupp T.R. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. Journal of Biological Chemistry 2001, 276(February):4699.
92. Lee M.K., Tong W.M., Wang Z.Q., Sabapathy K. Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo. Cell Death and Differentiation 2011, 18(February):214.
93. Slee E.A., Benassi B., Goldin R., Zhong S., Ratnayaka I., Blandino G., et al. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(November):19479.
94. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nature Cell Biology 2005, 7(February):165.
95. Feng L., Lin T., Uranishi H., Gu W., Xu Y. Functional analysis of the roles of posttranslational modifications at the p53C terminus in regulating p53 stability and activity. Molecular and Cellular Biology 2005, 25(July):5389.
96. Krummel K.A., Lee C.J., Toledo F., Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(July):10188.
97. Wang Y.V., Leblanc M., Fox N., Mao J.H., Tinkum K.L., Krummel K., et al. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes and Development 2011, 25(July):1426.
98. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Molecular and Cellular Biology 2006, 26(September):6859.
99. Marine J.C., Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochemical and Biophysical Research Communications 2005, 331(June):750.
100. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nature Reviews Cancer 2006, 6(September):663.
101. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(December):15608.
102. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358(July):80.
103. Parant J., Chavez-Reyes A., Little N.A., Yan W., Reinke V., Jochemsen A.G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genetics 2001, 29(September):92.
104. Finch R.A., et al. mdmx is a negative regulator of p53 activity in vivo. Cancer Research 2002, 62(June):3221.
105. Migliorini D., Lazzerini Denchi E., Danovi D., Jochemsen A., Capillo M., Gobbi A., et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Molecular and Cellular Biology 2002, 22(August):5527.
106. Xiong S., Pant V., Suh Y., Van Pelt C.S., Wang Y., Valentin -Vega Y.A., et al. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Research 2010, 70(September):7148.
107. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine 2012, 18(August):1239.
108. Laurie N.A., Donovan S.L., Shih C.S., Zhang J., Mills N., Fuller C., et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444(November):61.
109. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(July):8292.
110. Pomerantz J., Schreiber-Agus N., Liégeois N.J., Silverman A., Alland L., Chin L., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92(March):713.
111. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., et al. The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO Journal 1998, 17(September):5001.
112. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91(November):649.
113. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(March):823.
114. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445(February):661.
115. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., et al. Temporal dissection of p53 function in vitro and in vivo. Nature Genetics 2005, 37(July):718.
116. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127(December):1323.
117. Junttila M.R., Karnezis A.N., Garcia D., Madriles F., Kortlever R.M., Rostker F., et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010, 468(November):567.
118. Feldser D.M., Kostova K.K., Winslow M.M., Taylor S.E., Cashman C., Whittaker C.A., et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010, 468(November):572.